Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
ATAI Life SciencesN. V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders.
Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder.
The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD.
ATAI Life SciencesN. V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 24 | 0.00 Increased by +100.00% | -0.18 Increased by +100.00% |
| Mar 28, 24 | -0.12 Increased by +57.14% | -0.16 Increased by +25.00% |
| Nov 14, 23 | -0.28 Decreased by -27.27% | -0.20 Decreased by -40.00% |
| Aug 10, 23 | -0.21 Increased by +12.50% | -0.21 |
| May 11, 23 | -0.21 Increased by +12.50% | -0.21 |
| Mar 24, 23 | -0.28 Increased by +54.84% | -0.23 Decreased by -21.74% |
| Nov 10, 22 | -0.22 Decreased by -4.76% | -0.23 Increased by +4.35% |
| Aug 15, 22 | -0.24 Increased by +35.14% | -0.23 Decreased by -4.35% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 87.00 K Increased by +262.50% | 44.24 M Increased by +232.99% | Increased by +50.86 K% Increased by +136.69% |
| Jun 30, 23 | 172.00 K Increased by +1.18% | -33.04 M Decreased by -7.08% | Decreased by -19.21 K% Decreased by -5.84% |
| Mar 31, 23 | 37.00 K Increased by +N/A% | -33.32 M Decreased by -4.25% | Decreased by -90.06 K% Decreased by N/A% |
| Dec 31, 22 | 38.00 K Decreased by -83.48% | -45.32 M Increased by +49.00% | Decreased by -119.27 K% Decreased by -208.66% |
| Sep 30, 22 | 24.00 K Decreased by -90.98% | -33.27 M Decreased by -6.78% | Decreased by -138.62 K% Decreased by -1.08 K% |
| Jun 30, 22 | 170.00 K Increased by +N/A% | -30.86 M Increased by +36.33% | Decreased by -18.15 K% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by -100.00% | -31.96 M Decreased by -4.75 K% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 230.00 K Increased by +N/A% | -88.88 M Decreased by -2.64% | Decreased by -38.64 K% Decreased by N/A% |